On Friday, the Indian Drug Controller General (DCGI) authorised Reliance Life Sciences, owned by Mukesh Ambani, to conduct a phase I clinical trial with certain conditions of its indigenous COVID 19 vaccine.
They said that the phase-I clinical trial will assess SARS-CoV-2 vaccine for recombinant protein in healthy volunteers according to their safety, tolerability, and immunogenicity.
The firm is required to submit the revised clinical trial protocol for immunogenicity to be assessed on Day 42, instead of Day 14, as recommended by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation, a source said, citing the conditions set for the trial.
The DCGI gave the permission based on the recommendations given by the SEC which deliberated on the company’s application on August 26.
The trials will be conducted at eight sites in Maharashtra.
India’s drug regulator has so far issued emergency use authorisation to six COVID-19 vaccines — Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Zydus Cadila’s ZyCoV-D, Russian-made Sputnik V and the two made by US firms Moderna and Johnson & Johnson.
Recent Posts
Holi and Eye Safety: Protect Your Vision During Festivities
Holi, the festival of colors, is one of the most vibrant and joyous celebrations in…
FDA Recalls Popular Skincare Products Over Cancer-Causing Chemical
In a major development, the U.S. Food and Drug Administration (FDA) has issued recalls for…
Kidney Transplant Crisis: Why 98% of Patients in Delhi Die Waiting
In Delhi, the struggle for kidney transplant patients is a dire one. Less than 2%…
Diabetes & Eye Health: Why Regular Screening Matters
Diabetes is a chronic condition that affects millions of people worldwide. It occurs when the…
What Happens to Your Body in the First 72 Hours After Quitting Smoking?
Quitting smoking is one of the most significant steps you can take to improve your…
Deadly Flu Outbreak in Delhi-NCR: Hospitals Overwhelmed
As the warmer months set in, Delhi-NCR is witnessing an alarming surge in flu cases,…